Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference142 articles.
1. Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
2. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
3. Vasculae Reactions of Normal and Malignant Tissues in Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants
4. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
5. Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CSF-1R promotes vasculogenic mimicry via epithelial-mesenchymal transition in nasopharyngeal carcinoma cells;Oncologie;2023-04-12
2. Mechanoregulation of Vascular Endothelial Growth Factor Receptor 2 in Angiogenesis;Frontiers in Cardiovascular Medicine;2022-01-11
3. Current Anti-angiogenic Therapies and Their Limitations;Nanoparticles in Angiogenesis and Cancer;2022
4. Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer;Cancers;2020-10-20
5. Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding the Anti-Angiogenesis Resistance Mechanisms;International Journal of Molecular Sciences;2020-01-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3